Riskpilot← Back to searchSign inGet full accessHG Nordic Pharma AB
ABActiveOrg 5590204417Economic activity was not specified by tax authority · NACE 0000Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
-47% vs 2023
Equity ratio
95.6%
Financial strength
Net profit 2024
SEK -14K
-51% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -14K | -47% |
| Net profit | SEK -14K | -51% |
| Total assets | SEK 84K | -14% |
| Equity | SEK 81K | -15% |
| Employees | 0 | — |
Legal name
HG Nordic Pharma AB
Org number
5590204417
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
10 juli 2015
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Firman tecknas ensam av Wang, Jiang
Company purpose
Bolaget ska bedriva forskning, utveckling, tillverkning, marknadsföring, försäljning och investering inom biovetenskapliga produkter, och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | — | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −11 | −11 | −82 | −10 | −14 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −11 | −11 | −82 | −10 | −14 |
| Net financials | — | — | — | — | −0 |
| Profit before tax | −11 | −11 | −82 | −10 | −14 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −11 | −11 | −82 | −10 | −14 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 197 | 190 | 110 | 98 | 84 |
| Equity | 52 | 51 | 50 | 95 | 81 |
| Long-term debt | 145 | 135 | 54 | 0 | — |
| Short-term debt | 0 | 4 | 5 | 3 | 4 |
| Total debt | 145 | 139 | 59 | 3 | 4 |
EBITDA margin
-1400400.0%
This company
15.8%
Market median
-8863391% vs market
20202024
Equity ratio
95.6%
This company
38.2%
Market median
+150% vs market
20202024
Return on equity
-17.9%
This company
18.4%
Market median
-197% vs market
20202024
Net profit margin
-1444300.0%
This company
8.1%
Market median
-17830964% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JJ Chief Executive Officer | Chief Executive Officer | 2022 |
JW External Signatory | External Signatory | 2022 |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HG Nordic Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jack Jiang Yu | Chief Executive Officer | 0 companies |
| Jiang Wang | External Signatory | 0 companies |
| Zhiwei Li | Chairman | 0 companies |
| Qun Gu | Deputy Board Member | 0 companies |